Format

Send to

Choose Destination
See comment in PubMed Commons below
Future Med Chem. 2013 Apr;5(6):653-76. doi: 10.4155/fmc.13.38.

Boron chemicals in diagnosis and therapeutics.

Author information

1
Division of Hematology & Oncology, Department of Internal Medicine, Kansas University Medical Center, Kansas City, KS 66103, USA. bdas@kumc.edu

Abstract

Advances in the field of boron chemistry have expanded the application of boron from material use to medicine. Boron-based drugs represent a new class of molecules that possess several biomedical applications including use as imaging agents for both optical and nuclear imaging as well as therapeutic agents with anticancer, antiviral, antibacterial, antifungal and other disease-specific activities. For example, bortezomib (Velcade(®)), the only drug in clinical use with boron as an active element, was approved in 2003 as a proteasome inhibitor for the treatment of multiple myeloma and non-Hodgkin's lymphoma. Several other boron-based compounds are in various phases of clinical trials, which illustrates the promise of this approach for medicinal chemists working in the area of boron chemistry. It is expected that in the near future, several boron-containing drugs should become available in the market with better efficacy and potency than existing drugs. This article discusses the current status of the development of boron-based compounds as diagnostic and therapeutic agents in humans.

PMID:
23617429
PMCID:
PMC3703777
DOI:
10.4155/fmc.13.38
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon Icon for PubMed Central
    Loading ...
    Support Center